Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Research and Development Expenses (Q4 2025): $9.9 million, up from $6 million in Q4 2024. Research and Development Expenses (Full Year 2025): $33.7 million, up from $19.4 million in 2024. Net Loss (Q4 2025): $12.3 million, compared to $12.1 million in Q4 2024. Noncash Losses (Q4 2025): $0.7 million from equity method investment in Angel Pharmaceuticals and $2.3 million from change in fair value of warrant liability. Total Stock Compensation Expense (Q4 2025): $1.6 million, compared to $0.8 million in Q4 2024. Cash, Cash Equivalents, and Marketable Securities (As of Dec 31, 2025): $56.8 million, up from $52 million as of Dec 31, 2024. Pro Forma Cash (Including January 2026 Financing): Approximately $246 million, extending cash runway into Q2 2028. Warning! GuruFocus has detected 1 Warning Sign with CRVS. Is CRVS fairly valued? Test your thesis with our free DCF calculator. Release Date: March 12, 2026 For the complete tran
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.MarketBeat
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
CRVS
Earnings
- 3/12/26 - Miss
CRVS
Sec Filings
- 3/13/26 - Form 8-K
- 3/13/26 - Form 424B5
- 3/13/26 - Form S-3ASR
- CRVS's page on the SEC website